PL2075007T3 - Leczenie choroby Alzheimera - Google Patents

Leczenie choroby Alzheimera

Info

Publication number
PL2075007T3
PL2075007T3 PL08170222T PL08170222T PL2075007T3 PL 2075007 T3 PL2075007 T3 PL 2075007T3 PL 08170222 T PL08170222 T PL 08170222T PL 08170222 T PL08170222 T PL 08170222T PL 2075007 T3 PL2075007 T3 PL 2075007T3
Authority
PL
Poland
Prior art keywords
disease
alzheimer
treatment
medicament
preparation
Prior art date
Application number
PL08170222T
Other languages
English (en)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Publication of PL2075007T3 publication Critical patent/PL2075007T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08170222T 2003-05-08 2004-05-03 Leczenie choroby Alzheimera PL2075007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP08170222.7A EP2075007B9 (en) 2003-05-08 2004-05-03 Treatment for Alzheimer's disease
EP04730882A EP1623719B1 (en) 2003-05-08 2004-05-03 Treatment of alzheimer's disease and cerebral amyloid angiopathy

Publications (1)

Publication Number Publication Date
PL2075007T3 true PL2075007T3 (pl) 2013-09-30

Family

ID=32982086

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej

Country Status (19)

Country Link
US (6) US20090162362A1 (pl)
EP (5) EP1623719B1 (pl)
JP (5) JP2006525288A (pl)
CN (2) CN101264326A (pl)
AT (1) ATE435024T1 (pl)
AU (2) AU2004237373A1 (pl)
BR (1) BRPI0410684A (pl)
CA (1) CA2524571C (pl)
CY (1) CY1109454T1 (pl)
DE (1) DE602004021797D1 (pl)
DK (3) DK1623719T3 (pl)
ES (6) ES2246178B1 (pl)
IL (8) IL171651A (pl)
MX (1) MXPA05010914A (pl)
PL (3) PL2356996T3 (pl)
PT (3) PT1623719E (pl)
RU (2) RU2385161C2 (pl)
SI (1) SI1623719T1 (pl)
WO (1) WO2004098631A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
ES2454253T3 (es) 2005-12-12 2014-04-10 Ac Immune S.A. Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2445590T3 (es) * 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
RU2571859C2 (ru) * 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
DK2510359T3 (en) 2009-12-11 2015-12-07 Araclón Biotech S L METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID-BETA PEPTIDES
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2573135T3 (es) * 2010-07-14 2016-06-06 Merck Sharp & Dohme Corp. Anticuerpo monoclonal anti-ADDL y usos del mismo
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
DE69126304T2 (de) 1990-04-27 1997-09-04 Mcmichael, John, Delanson, N.Y. Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
JP3980833B2 (ja) * 1998-08-20 2007-09-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア βアミロイド斑及び神経原線維変化の標識方法
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
EP2356996B9 (en) 2013-08-28
IL207875A0 (en) 2011-07-31
PT2075007E (pt) 2013-08-23
CN1784240A (zh) 2006-06-07
US20170260234A1 (en) 2017-09-14
AU2011200170A1 (en) 2011-02-03
EP1623719B1 (en) 2009-07-01
DK2356996T5 (da) 2013-08-26
PT1623719E (pt) 2009-10-08
US20210214394A1 (en) 2021-07-15
ES2423590T3 (es) 2013-09-23
ES2329369T3 (es) 2009-11-25
ES2246178B1 (es) 2007-03-01
WO2004098631A1 (es) 2004-11-18
MXPA05010914A (es) 2006-03-21
AU2011200170C1 (en) 2012-03-22
IL207881A0 (en) 2011-07-31
EP2075007B9 (en) 2013-09-04
IL207879A (en) 2013-02-28
DE602004021797D1 (de) 2009-08-13
US20140044725A1 (en) 2014-02-13
EP2305286A2 (en) 2011-04-06
JP2014129389A (ja) 2014-07-10
BRPI0410684A (pt) 2006-06-20
JP2012006967A (ja) 2012-01-12
IL207877A0 (en) 2011-07-31
ES2246105A1 (es) 2006-02-01
PT2356996E (pt) 2013-08-23
EP2082747A3 (en) 2010-01-13
EP2075007A2 (en) 2009-07-01
IL207880A0 (en) 2011-07-31
IL207879A0 (en) 2011-07-31
RU2526155C2 (ru) 2014-08-20
US20110262458A1 (en) 2011-10-27
JP2018119011A (ja) 2018-08-02
IL171651A (en) 2011-11-30
EP1623719A1 (en) 2006-02-08
IL207880A (en) 2013-02-28
ES2246177A1 (es) 2006-02-01
JP2016065100A (ja) 2016-04-28
PL2356996T3 (pl) 2013-09-30
JP2006525288A (ja) 2006-11-09
RU2385161C2 (ru) 2010-03-27
PL1623719T3 (pl) 2010-11-30
ATE435024T1 (de) 2009-07-15
IL207877A (en) 2013-03-24
EP2305286A3 (en) 2011-11-09
RU2009148539A (ru) 2011-06-27
CA2524571A1 (en) 2004-11-18
US20200140488A1 (en) 2020-05-07
AU2011200170B2 (en) 2011-09-01
ES2246105B1 (es) 2007-03-01
EP2356996B1 (en) 2013-06-26
US20090162362A1 (en) 2009-06-25
IL207875A (en) 2013-02-28
IL207878A (en) 2013-02-28
SI1623719T1 (sl) 2009-12-31
EP2356996A1 (en) 2011-08-17
IL207881A (en) 2013-02-28
DK1623719T3 (da) 2009-11-09
IL207876A (en) 2013-03-24
IL207876A0 (en) 2011-07-31
ES2246177B1 (es) 2007-03-01
AU2004237373A1 (en) 2004-11-18
EP2075007B1 (en) 2013-05-22
ES2423281T3 (es) 2013-09-19
DK2356996T3 (da) 2013-07-22
CA2524571C (en) 2017-01-10
IL207878A0 (en) 2011-07-31
CY1109454T1 (el) 2014-08-13
EP2075007A3 (en) 2009-11-11
CN101264326A (zh) 2008-09-17
EP2082747A2 (en) 2009-07-29
ES2246178A1 (es) 2006-02-01
RU2005134351A (ru) 2006-04-27
DK2075007T3 (da) 2013-07-29

Similar Documents

Publication Publication Date Title
PL2356996T3 (pl) Leczenie choroby Alzheimera
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
WO2002074240A3 (en) Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
AT500379A3 (de) Tau-proteine
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
EP1543109A4 (en) SUBSTANCES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
EP1377287A4 (en) PROANTHOCYANIDINES FOR THE TREATMENT OF AMYLOSES AND ALPHA-SYNUCLEIN-INDUCED DISEASES
WO2010024927A3 (en) Treatment of amyloidoses using myelin basic protein and fragments thereof
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
EP1614428A4 (en) MEDICAMENT FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES